AbbVie (ABBV) Tops Q2 EPS by 1c; raises guidance

AbbVie (NYSE: ABBV) reported Q2 EPS of $2.97, $0.01 better than the analyst estimate of $2.96. Revenue for the quarter came in at $15.42 billion versus the consensus estimate of $14.99 billion.

GUIDANCE:

AbbVie sees FY2025 EPS of $11.88-$12.08, versus the consensus of $11.98.

For earnings history and earnings-related data on AbbVie (ABBV) click here.

You May Also Be Interested In

• EU approves AbbVie's Maviret for acute hepatitis C treatment
• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• BE Semiconductor (BESI:NA) (BESIY) PT Raised to EUR400 at Needham